CSL (ASX:CSL) - Aktienkurs, Nachrichten und Analyse

CSL Aktienübersicht

CSL grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	2/6
Künftiges Wachstum	3/6
Vergangene Leistung	5/6
Finanzielle Gesundheit	4/6
Dividenden	0/6

Belohnungen

12% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 12.85% pro Jahr

Die Erträge stiegen im vergangenen Jahr um 20.4%

Risikoanalyse

Hat einen hohen Schuldenstand

CSL Limited Wettbewerber

Telix Pharmaceuticals

ASX:TLX

AU$6.8b

Clinuvel Pharmaceuticals

ASX:CUV

AU$714.3m

Gilead Sciences

NasdaqGS:GILD

US$103.4b

Regeneron Pharmaceuticals

NasdaqGS:REGN

US$112.5b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für CSL
Historische Aktienkurse
Aktueller Aktienkurs	AU$285.10
52-Wochen-Hoch	AU$313.55
52-Wochen-Tief	AU$228.65
Beta	0.33
11 Monat Veränderung	-7.41%
3 Monate Veränderung	-3.42%
1 Jahr Veränderung	13.68%
33 Jahre Veränderung	-1.31%
5 Jahre Veränderung	20.63%
Veränderung seit IPO	35,537.86%

Aktuelle Nachrichten und Updates

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

Recent updates

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Sep 18

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Sep 03

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Aug 16

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Aug 07

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

May 22

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

May 01

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

Aug 13

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

May 30

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

May 09

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Mar 01

Estimating The Fair Value Of CSL Limited (ASX:CSL)

Feb 07

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Nov 17

CSL Limited (ASX:CSL) Shares Could Be 24% Below Their Intrinsic Value Estimate

Oct 27

We Think CSL (ASX:CSL) Can Stay On Top Of Its Debt

Aug 19

Is CSL Limited (ASX:CSL) Trading At A 22% Discount?

Jul 29

CSL's (ASX:CSL) Problems Go Beyond Weak Profit

Feb 22

Is CSL Limited (ASX:CSL) Worth AU$270 Based On Its Intrinsic Value?

Jan 19

With EPS Growth And More, CSL (ASX:CSL) Is Interesting

Dec 08

Aktionärsrenditen

	CSL	AU Biotechs	AU Markt
7D	-2.9%	-2.5%	0.3%
1Y	13.7%	16.3%	16.1%

Rendite im Vergleich zur Industrie: CSL unter dem Niveau der Branche Australian Biotechs , die im vergangenen Jahr eine Rendite von 18% erzielte.

Rendite vs. Markt: CSL hinter dem Markt Australian zurück, der im vergangenen Jahr eine Rendite von 16.4 erzielte.

Preisvolatilität

Is CSL's price volatile compared to industry and market?
CSL volatility
CSL Average Weekly Movement	2.2%
Biotechs Industry Average Movement	10.4%
Market Average Movement	8.9%
10% most volatile stocks in AU Market	17.0%
10% least volatile stocks in AU Market	3.6%

Stabiler Aktienkurs: CSL hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: CSLDie wöchentliche Volatilität (2%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1916	32,698	Paul McKenzie	www.csl.com.au

CSL Limited erforscht, entwickelt, produziert, vermarktet und vertreibt Biopharmazeutika und Impfstoffe in Australien, den Vereinigten Staaten, Deutschland, dem Vereinigten Königreich, der Schweiz, China, Hongkong und international. Das Unternehmen ist in den Segmenten CSL Behring, CSL Seqirus und CSL Vifor tätig. Das Segment CSL Behring bietet Plasmaprodukte, Gentherapien und Rekombinanten an.

CSL Limited's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von CSL im Vergleich zum Marktanteil des Unternehmens?
CSL grundlegende Statistiken
Marktanteil	AU$138.05b
Gewinn(TTM)	AU$3.84b
Umsatz(TTM)	AU$21.50b

35.9x

Kurs-Gewinn-Verhältnis

6.4x

Kurs-Umsatz-Verhältnis

Ist CSL zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
CSL Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$14.80b
Kosten der Einnahmen	US$7.10b
Bruttogewinn	US$7.71b
Sonstige Ausgaben	US$5.06b
Umsatz	US$2.64b

Zuletzt gemeldete Gewinne

Jun 30, 2024

Datum des nächsten Gewinnberichts

Feb 11, 2025

Gewinn per Aktie (EPS)	5.46
Bruttomarge	52.06%
Nettogewinnspanne	17.85%
Schulden/Eigenkapital-Verhältnis	54.2%

Wie hat sich CSL auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

1.3%

Aktuelle Dividendenrendite

48%

Ausschüttungsquote

CSL Aktienübersicht

Belohnungen

Risikoanalyse

CSL Limited Wettbewerber

ASX:TLX

AU$6.8b

ASX:CUV

AU$714.3m

NasdaqGS:GILD

US$103.4b

NasdaqGS:REGN

US$112.5b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Recent updates

CSL (ASX:CSL) Gains Approval for Updated COVID-19 Vaccine in Japan, Boosting Strategic Alliances

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics Holdings Inc.'s Updated Self-Amplifying mRNA Covid-19 Vaccine for Protection Against JN.1 Strain

MD, CEO & Executive Director exercised options and sold AU$1.1m worth of stock

Getting In Cheap On CSL Limited (ASX:CSL) Is Unlikely

Upcoming dividend of US$1.45 per share

CSL Limited (ASX:CSL) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?

Final dividend of US$1.45 announced

Full year 2024 earnings: EPS misses analyst expectations

CSL Limited to Report First Half, 2025 Results on Feb 11, 2025

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 27% Undervalued

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

CSL Limited's (ASX:CSL) Price Is Out Of Tune With Earnings

An Intrinsic Calculation For CSL Limited (ASX:CSL) Suggests It's 20% Undervalued

Now 21% undervalued after recent price drop

CSL Vifor and Travere Therapeutics Announces European Commission Approves FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

Now 20% undervalued

CSL Seqirus Confirms Full Preparation to Implement the Fda's Vaccines and Related Biological Products Advisory Committee

Upcoming dividend of US$1.19 per share

First half dividend of US$1.19 announced

First half 2024 earnings: EPS misses analyst expectations

CSL Limited Announces Estimate Distribution for the Six Months Ended December 31, 2023, Payable on April 3, 2024

CSL Announces Top-Line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I (Human)

Now 22% undervalued

CSL Limited's (ASX:CSL) Earnings Haven't Escaped The Attention Of Investors

Now 21% undervalued

CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster

CSL Limited to Report Fiscal Year 2024 Results on Jul 30, 2024

CSL Behring's HEMGENIX (Etranacogene Dezaparvovec-Drlb) Demonstrates At Three Years Post-T Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia B

Is CSL (ASX:CSL) Using Too Much Debt?

Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults

CSL Limited (ASX:CSL) Shares Could Be 28% Below Their Intrinsic Value Estimate

Health Canada Authorizes Csl's Hemgenix(R) (Etranacogene Dezaparvovec) as First Gene Therapy for Hemophilia B

CSL Limited Reaffirms Financial Outlook for Fiscal Year 2024

CSL Seqirus Announces Data from Three Studies Supporting the Clinical, Public Health Benefit and Cost Savings Associated with Cell-Based and Adjuvanted Influenza Vaccines

CSL Seqirus Shares Data Demonstrating the Potential for Influenza Vaccination to Reduce the Burden on Healthcare Resources

These 4 Measures Indicate That CSL (ASX:CSL) Is Using Debt Reasonably Well

Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19

Upcoming dividend of US$1.29 per share at 1.4% yield

Independent Non-Executive Chairman recently sold AU$5.6m worth of stock

CSL Appoints Jeffrey Ball as First Chief Sustainability Officer

CSL Limited, Annual General Meeting, Oct 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

CSL Limited's (ASX:CSL) Intrinsic Value Is Potentially 47% Above Its Share Price

CSL Limited to Report Fiscal Year 2023 Results on Aug 15, 2023

CSL (ASX:CSL) Has A Pretty Healthy Balance Sheet

A Look At The Intrinsic Value Of CSL Limited (ASX:CSL)

Upcoming dividend of US$1.07 per share at 1.1% yield

Does CSL (ASX:CSL) Have A Healthy Balance Sheet?

First half 2023 earnings released: EPS: US$3.37 (vs US$3.85 in 1H 2022)

CSL Limited Announces Interim Dividend, Payable on 5 April 2023

Estimating The Fair Value Of CSL Limited (ASX:CSL)

CSL Limited, Annual General Meeting, Oct 11, 2023

CSL Limited to Report First Half, 2023 Results on Feb 14, 2023

SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases

CSL Limited Announces Management Changes

CSL Limited Announces Chief Executive Officer Changes

CSL Limited Announces FDA Approval of First Gene Therapy for Adults with Hemophilia B

CSL (ASX:CSL) Seems To Use Debt Quite Sensibly

Erträge & Einnahmen